×
About 17,669 results

ALLMedicine™ Cholangiocarcinoma Center

Research & Reviews  8,723 results

Prognostic significance of the neutrophil-to-lymphocyte ratio with distal cholangiocarc...
https://doi.org/10.1097/MD.0000000000022827
Medicine Ji F, Kang Q et. al.

Oct 30th, 2020 - The present study aimed to investigate the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) in distal cholangiocarcinoma (DCC) following radical surgery. The clinicopathological data of 59 patients with DCC were retrospectively reviewe...

Association Between Aspirin and Cholangiocarcinoma in a Large Asian Cohort.
https://doi.org/10.1001/jamaoncol.2020.5018
JAMA Oncology; Kim MH, Park SM et. al.

Oct 29th, 2020 - Association Between Aspirin and Cholangiocarcinoma in a Large Asian Cohort.|2020|Kim MH,Park SM,Chang J,Hwang IC,|

Long-term results of ERCP- or PTCS-directed photodynamic therapy for unresectable hilar...
https://doi.org/10.1007/s00464-020-08095-1
Surgical Endoscopy; Li Z, Jiang X et. al.

Oct 26th, 2020 - Photodynamic therapy (PDT) can be performed as palliative therapy for cholangiocarcinoma, while there is currently insufficient evidence for the efficacy. The aim of this study was to explore the clinical efficacy and safety of endoscopic retrogra...

The blockade of interleukin 33 released by hepatectomy would be a promising treatment o...
https://doi.org/10.1111/cas.14709
Cancer Science; Nagaoka S, Yamada D et. al.

Oct 24th, 2020 - Interleukin-33 (IL-33), an alarmin released during tissue injury, facilitates the development of cholangiocarcinoma (CCA) in a murine model. However, it is unclear whether IL-33 is associated with human CCA. The aim of this study was to support th...

Investigating effects of preoperative inflammatory biomarkers on predicting survival ou...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585228
World Journal of Surgical Oncology; Zhang Z, Zhou Y et. al.

Oct 24th, 2020 - Intrahepatic cholangiocarcinoma (ICC) stands as the second most common malignant tumor in the liver with poor patient prognosis. Increasing evidences have shown that inflammation plays a significant role in tumor progression, angiogenesis, and met...

see more →

Guidelines  13 results

Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline
http://ascopubs.org/doi/full/10.1200/JCO.18.02178

Mar 10th, 2019 - PURPOSE To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. METHODS ASCO convened an Expert Panel to conduct a systematic review of the literature on adju...

Clinical practice guidelines for IgG4-related sclerosing cholangitis.
https://doi.org/10.1002/jhbp.596
Journal of Hepato-biliary-pancreatic Sciences; Kamisawa T, Nakazawa T et. al.

Dec 23rd, 2018 - IgG4-related sclerosing cholangitis (IgG4-SC) is a distinct type of cholangitis frequently associated with autoimmune pancreatitis and currently recognized as a biliary manifestation of IgG4-related disease. Although clinical diagnostic criteria o...

Hilar cholangiocarcinoma: expert consensus statement.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527854
HPB : the Official Journal of the International Hepato Pancreato Biliary Association; Mansour JC, Aloia TA et. al.

Jul 14th, 2015 - An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus meeting of expert panellists met on 15 January 2014 to review current evidence on the management of hilar cholangiocarcinoma in order to establish practice guidelines and...

Asia-Pacific consensus recommendations for endoscopic and interventional management of ...
https://doi.org/10.1111/jgh.12128
Journal of Gastroenterology and Hepatology; Rerknimitr R, Angsuwatcharakon P et. al.

Jan 28th, 2013 - Hilar cholangiocarcinoma (HCCA) is one of the most common types of hepatobiliary cancers reported in the world including Asia-Pacific region. Early HCCA may be completely asymptomatic. When significant hilar obstruction develops, the patient prese...

Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update.
https://doi.org/10.1136/gutjnl-2011-301748
Gut Khan SA, Davidson BR et. al.

Aug 16th, 2012 - The British Society of Gastroenterology guidelines on the management of cholangiocarcinoma were originally published in 2002. This is the first update since then and is based on a comprehensive review of the recent literature, including data from ...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  8,845 results

Prognostic significance of the neutrophil-to-lymphocyte ratio with distal cholangiocarc...
https://doi.org/10.1097/MD.0000000000022827
Medicine Ji F, Kang Q et. al.

Oct 30th, 2020 - The present study aimed to investigate the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) in distal cholangiocarcinoma (DCC) following radical surgery. The clinicopathological data of 59 patients with DCC were retrospectively reviewe...

Association Between Aspirin and Cholangiocarcinoma in a Large Asian Cohort.
https://doi.org/10.1001/jamaoncol.2020.5018
JAMA Oncology; Kim MH, Park SM et. al.

Oct 29th, 2020 - Association Between Aspirin and Cholangiocarcinoma in a Large Asian Cohort.|2020|Kim MH,Park SM,Chang J,Hwang IC,|

Long-term results of ERCP- or PTCS-directed photodynamic therapy for unresectable hilar...
https://doi.org/10.1007/s00464-020-08095-1
Surgical Endoscopy; Li Z, Jiang X et. al.

Oct 26th, 2020 - Photodynamic therapy (PDT) can be performed as palliative therapy for cholangiocarcinoma, while there is currently insufficient evidence for the efficacy. The aim of this study was to explore the clinical efficacy and safety of endoscopic retrogra...

The blockade of interleukin 33 released by hepatectomy would be a promising treatment o...
https://doi.org/10.1111/cas.14709
Cancer Science; Nagaoka S, Yamada D et. al.

Oct 24th, 2020 - Interleukin-33 (IL-33), an alarmin released during tissue injury, facilitates the development of cholangiocarcinoma (CCA) in a murine model. However, it is unclear whether IL-33 is associated with human CCA. The aim of this study was to support th...

Investigating effects of preoperative inflammatory biomarkers on predicting survival ou...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585228
World Journal of Surgical Oncology; Zhang Z, Zhou Y et. al.

Oct 24th, 2020 - Intrahepatic cholangiocarcinoma (ICC) stands as the second most common malignant tumor in the liver with poor patient prognosis. Increasing evidences have shown that inflammation plays a significant role in tumor progression, angiogenesis, and met...

see more →

News  63 results

FDA Approves First Targeted Drug for Bile Duct Cancer
https://www.medscape.com/viewarticle/928959

Apr 19th, 2020 - The US Food and Drug Administration (FDA) has granted accelerated approval of a new targeted therapy for use in some patients with cholangiocarcinoma, a rare cancer of the bile ducts. The product is pemigatinib (Pemazyre, Incyte), an oral kinase i...

Fast Five Quiz: Cholangiocarcinoma Presentation and Diagnosis
https://reference.medscape.com/viewarticle/922403

Feb 19th, 2020 - Cancer of the bile duct, or cholangiocarcinoma, is a malignant neoplasm of the intrahepatic or extrahepatic biliary epithelium. It is the most common biliary tract cancer and the second most common primary hepatic cancer. Although its etiology is ...

Fast Five Quiz: Cholangiocarcinoma Presentation and Diagnosis
https://reference.medscape.com/viewarticle/922403_1

Feb 19th, 2020 - Cancer of the bile duct, or cholangiocarcinoma, is a malignant neoplasm of the intrahepatic or extrahepatic biliary epithelium. It is the most common biliary tract cancer and the second most common primary hepatic cancer. Although its etiology is ...

Combo Tx Helpful for Selected Unresectable ICC Patients
https://www.medpagetoday.com/hematologyoncology/othercancers/83093

Nov 1st, 2019 - The combination of locoregional treatment approaches with systemic chemotherapy may offer improved outcomes for some patients with unresectable intrahepatic cholangiocarcinoma (ICC), according to the results of two single-arm, phase II studies. Th...

November 2019
https://www.mdedge.com/gihepnews/article/211213/november-2019?channel=29259

Oct 30th, 2019 - Q1. Correct answer: F Rationale There are a number of known risk factors for cholangiocarcinoma including PSC, choledochal cysts, obesity, chronic liver disease, toxins such as Thorotrast as well as liver flukes including those in the Opisthorchis.

see more →

Patient Education  23 results see all →